People are running their own experiments with GLP-1s — with stunning results
People are running their own experiments with GLP-1s — with stunning results
People are running their own experiments with GLP-1s — with stunning results
Shownote
Shownote
GLP-1 drugs like Ozempic and Wegovy are being taken by millions of Americans.
These medications have been approved for treating diabetes, obesity, and a small
number of other chronic conditions. But even as experts are still learning how
the drugs work, many people have found that they help with other disorders —
from addiction to brain fog to arthritis — where anecdotal evidence is promising
but the formal research hasn’t caught up. Julia Belluz
[https://www.juliabelluz.com/], a contributing writer for the New York Times
Opinion section and coauthor of Food Intelligence
[https://books.apple.com/us/book/food-intelligence/id6739794014], joins Apple
News In Conversation guest host David Greene to explain why what’s unfolding
right now may be the largest uncontrolled drug experiment in modern history.
Highlights
Highlights
This podcast explores the rapidly expanding use of GLP-1 drugs like Ozempic and Wegovy, moving beyond their approved uses for diabetes and obesity. It examines the phenomenon of people using these medications for a wide range of off-label conditions, creating what experts describe as a large-scale, uncontrolled experiment with unknown long-term consequences.
Chapters
Chapters
How GLP-1 Drugs Rewire the Brain, Not Just the Stomach
00:00The Uncontrolled Experiment: Off-Label Use for Addiction, IBS, and More
05:53Unknown Risks and the Gray Market: What Happens When Data Can't Keep Up?
15:00A 600% Spike in Kids: Are We Experimenting on Developing Brains?
21:00Transcript
Transcript
Speaker 3: This is In Conversation from Apple News. I'm David Greene, in for Shumita Basu. Today, the GLP-1 experiment happening in real time. Millions of people in the U.S. Are taking GLP-1 medications right now, an estimated one in eight adults. You prob...

